123
Participants
Start Date
April 26, 2017
Primary Completion Date
April 19, 2019
Study Completion Date
April 26, 2019
ADX-102 Ophthalmic Solution (0.5%)
ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
Vehicle of ADX-102 Ophthalmic Solution
Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
John Hopkins, Baltimore
Virginia Eye Consultants, Norfolk
Levenson Eye Associates, Jacksonville
Center for Retina and Macular Disease, Winter Haven
UAB Department of Ophthalmology, Birmingham
Midwest Eye Institute, Indianapolis
Oakland Ophthalmic Surgery, Birmingham
Bergstrom Eye Research, Fargo
Tauber Eye Center, Kansas City
Texas Retina Associates, Dallas
Retina Consultants of Houston, Houston
Retina Consultants of Houston, The Woodlands
Retina and Uveitis Consultants of Texas, San Antonio
Corneal Consultants of Colorado, Littleton
Retinal Research Institute, Phoenix
Byers Eye Institute at Stanford University, Palo Alto
Walman Eye Center, Sun City
M&M Eye Institute, Prescott
Retina-Vitreous Associates Medical Group, Beverly Hills
University of California, Irvine, Irvine
Retinal Consultants Medical Group, Inc., Sacramento
Oregon Retina, LLP, Eugene
Danbury Eye Physicians & Surgeons, Danbury
Valley Eye Physicians & Surgeons, Ayer
Ophthalmic Consultants of Boston, Boston
Ocular Immunology & Uveitis Foundation, Waltham
Metropolitan Eye Research and Surgery Institute, Palisades Park
Lead Sponsor
Aldeyra Therapeutics, Inc.
INDUSTRY